Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease

NCT01849250 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01849250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01849250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2013
Completion date
April 22, 2020
Enrollment
65 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

benign breast neoplasm, ductal breast carcinoma in situ, invasive breast carcinoma, lobular breast carcinoma in situ, paget disease of the breast, stage ia breast cancer, stage ib breast cancer, stage iia breast cancer, stage iib breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer